According to recent international studies reported by MedicalXpress, the drug sac-TMT (sacituzumab tirumotecan) has been found to reduce recurrence or death from endometrial cancer.
The Process
After attaching to proteins on tumor cells, sac-TMT delivers targeted doses of a substance leading to the death of the cancer cells.
The Study
All study participants had been successfully treated with pembrolizumab (Keytruda), an established PD-1 inhibitor drug that makes cancer cells more visible to an immune system attack.
Cancers of the lining of the female endometrium (uterus) are the most common. Researchers at NYU Langone Health who led the study acknowledge that there have been few effective options to treat the disease, especially when diagnosed late.
The study called for Sac-TMT to be compared to standard chemotherapy drugs such as Keytruda (pembrolizumab) a PD-1 inhibitor that increases exposure of cancer cells to an immune system attack. Immunotherapy is applicable in cases of recurring or advanced endometrial cancer.
Phase III Trial
A total of 386 women who were randomly selected to receive sac-TMT following immunotherapy reported a 41% lower risk of their cancer progressing as compared to 390 endometrial cancer survivors treated with chemotherapy alone.
The overall risk of death associated with the sac-TMT group was 32% lower than the standard chemotherapy-treated group. All study participants had been successfully treated with pembrolizumab (Keytruda), an established PD-1 inhibitor drug that makes cancer cells more visible to immune system attack.
More than twice as many women treated with sac-TMT showed a response, such as tumor shrinkage, than those treated with standard chemotherapy. Side effects in the sac-TMT group were manageable according the researchers.
Data from NCT06132958, presented at the ESMO was published online in The Lancet.
What are your thoughts about becoming a rare disease advocate? Share your hopes, thoughts, and stories with the Patient Worthy Community
Rose Duesterwald November 2, 2026
